{"id":"W1516639348","doi":"10.1158/1538-7445.sabcs14-s6-04","title":"Abstract S6-04: Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: Overall survival from the Phase II ‘FIRST’ study","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Fulvestrant; Anastrozole; Medicine; Hazard ratio; Internal medicine; Clinical endpoint; Metastatic breast cancer; Oncology; Breast cancer; Phases of clinical research; Cancer; Confidence interval; Tamoxifen; Randomized controlled trial; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007886052,0.0005482918,0.0008196499,0.0001575707,0.0008155288,0.00008781837,0.0005850175,0.0001343512,0.000934827],"category_scores_gemma":[0.0001667065,0.0003829469,0.0002341526,0.0005106236,0.000408856,0.0004736577,0.0001818996,0.0006485844,0.00004768137],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003031794,"about_ca_system_score_gemma":0.001987402,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.02540178,"about_ca_topic_score_gemma":0.01888983,"domain_scores_codex":[0.9953771,0.000145576,0.0005572604,0.001044761,0.001551205,0.001324122],"domain_scores_gemma":[0.9960897,0.000832264,0.0001779851,0.001186571,0.0009452867,0.000768225],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.2999511,0.01388509,0.01460671,0.000271133,0.004843694,0.0004956904,0.01561587,0.009526202,0.01766761,0.0002446168,0.00535864,0.6175336],"study_design_scores_gemma":[0.3276633,0.04582696,0.07309281,0.001280426,0.0009770858,0.00005562262,0.02059683,0.0005451365,0.01135285,0.001113229,0.515862,0.001633647],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9669524,0.00575466,0.00008393194,0.01899014,0.001190722,0.004205298,0.002449838,0.0001279604,0.0002450562],"genre_scores_gemma":[0.9905404,0.001483498,0.0001663226,0.0002036215,0.002480222,0.003763366,0.0001834403,0.0001420189,0.001037053],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6159,"threshold_uncertainty_score":0.9999785,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1979236632696527,"score_gpt":0.4825408365740193,"score_spread":0.2846171733043665,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}